×

The Blog

Building a Future Free of Age-Related Disease

Waking up From the Dream of Longevity

In the course of the last century, science fiction has been a harbinger of things to come. From the automatic sliding doors of Star Trek to visual communication, cyberspace, and even the moon landing, many of our present technological achievements were dreamed up in the futuristic visions of science fiction authors of the 1960s and 70s. Indeed, the fantastical world of science fiction, while not intended to be prophetic, has ended up acting as a blueprint for our modern world.

We have learned from science fiction not only the possibilities of technology, however, but also its irreconcilable dangers. Readers of the genre will recognize the many stories warning us of the hazards of space travel, mind enhancement, and artificial intelligence. These fictional accounts cautioned that if we were not careful, our freedom to transform the world around us would transmogrify into a self-enforced slavery.

Nonetheless, while many of us remembered that these were just stories, intended as speculations about a possible future—in other words, they were fiction before science—through them, we became used to the idea that any advanced technology was inherently dangerous and its use always suspect. Moreover, it became a commonplace idea that technologies whose aim was to change or transform the human being—whether genetic, biological or reconstructive—would lead to a future worthy of Mary Shelley’s Frankenstein.

Paradoxically, science fiction became the torchbearer of the dystopian consequences of unhindered technological progress and showed us a world in which, instead of an optimistic balance between progress and responsibility, an excessive use of technology would lead to our replacement by a host of loving, graceful machines.

Furthermore, the extension of life through scientific means was, until the last few decades, another mainstay motif of science fiction stories and was portrayed as a pretty perilous idea. In many of these stories, the desire for longevity or immortality was often presented as a false goal or as part of a cautionary tale against the narcissistic wish to meddle with nature. In some cases, such as Borges’ “The Immortal”, the struldbrugs in “Gulliver’s Travels” or Moorcock’s “Dancers at the End of Time”, a longer life brought with it the loss of motivation and meaning, as boredom and stagnation became the bulwarks of an ageless society.

In others, overpopulation was to be the deciding factor in the undesirability of longevity, as in Richard Wilson’s “The Eight Billion”, in which this number is described as the population of New York alone following the discovery of a means to extend human life indefinitely. Others still, such as Roger Zelazny’s “The Immortal” and Richard Morgan’s “Altered Carbon”, worried that rejuvenation, if it ever came about, would only be available to the rich, further segregating society into those who could afford to live free of the ravages of aging and those who could not.

Without a doubt, these warnings raise important concerns regarding social inequality and resource management in a world where humans can greatly exceed their expected lifespan. Curiously, similar arguments about an untenable population explosion, a loss of meaning, boredom, and inequality are also the primary objections put forth by those who oppose the scientific pursuit of longevity today. Nevertheless, as important as these are to consider, they might be more suitable for the above-mentioned fictional accounts than to the modest scientific work presently underway.

Certainly, the interest in life extension has taken an enormous leap forward in the last two decades, both in the efforts carried out by scientists across the globe to understand and mitigate the causes of aging itself, and in the explosion of stories and debates on the subject, particularly in the news, public media, podcasts, and television shows.

Today’s search for a longer life is very different to that described by the science fiction of the last century, however. Instead of a common societal effort to cheat death, or a heroic quest to find the fountain of youth, current scientific attempts to treat aging are based on the much more long-term and human-scale work of understanding what aging is to begin with, how it occurs in living organisms, and whether it is possible to prevent or reduce the damages associated with it. To the dismay of some, the focus of aging research is much less grandiose than our former stories might have anticipated, and the spotlight is not on a desire to live forever but on a humanitarian effort to reduce suffering by eradicating age-related diseases.

Nevertheless, the exponential rise in the number of news stories written about longevity indicates that the science fiction of the 20th century has become the science fact of the 21st. In the last few years, we have seen articles on the science of longevity published in every major newspaper, including the New York Times, the Guardian, the Globe and Mail, and Le Monde, to name but a few.

This has been complemented by a parallel upsurge in newscasts and interviews with leading researchers as well as attracting the interest of major investors, including the likes of Google, Larry Ellison, and Jim Mellon along with Silicon Valley startups such as Unity Biotechnology. A simple Google search for news containing stories about human longevity shows the stark difference in interest between the year 2000 (0 results!), and 2018, where more than 800 news stories have already been released, and that is only in the last two months!

The biology of aging has emerged as a real science with the potential to change the way we see health and lifespan in the coming years. The distant dreams of science fiction of the last half-century have become a present reality in which the rapid advances of science and technology offer us, for the first time in human history, the real possibility to undo the damages caused by aging.

Once again, however, we should tread carefully when equating the fictional speculations of our storytellers with that of the scientific pursuit of understanding the mechanisms of aging. It is high time we begin putting the science before the fiction. The day has come to wake up from the dreams of the past and take an active role in building a present in which a life free of aging and unnecessary suffering is not only possible but is pursued as a solution to a real problem that, today, concerns each one of us.

Gene Cocktail Helps Hearts to Regenerate

The human heart is an organ whose cells rarely divide, making tissue repair and regeneration a huge problem following a heart attack. Many animals, such as zebrafish and salamanders, are different; they can regenerate damaged hearts easily.

As humans, we also once had the same regenerative capacity during our early development, but after we were born, we lost this ability. This is also true for many other organs, including the brain, spinal cord, and pancreas. The cells in these tissues divide very rarely if at all, and this is a big problem. But, what if we could get that regenerative ability back and repair damage to our hearts the way these amazing animals do?

Researchers have been trying for decades to find out how we can enjoy the same tissue regeneration, but they have met with limited success—until now.

Unlocking cell division in cardiomyocytes

A research team led by Dr. Deepak Srivastava, president of the Gladstone Institutes, has finally achieved this long sought-after goal in a study published in the journal Cell[1]. The researchers have developed an efficient and reliable way of making non-dividing adult cardiomyocytes divide so that they can repair damaged hearts.

They identified four genes that regulate cell division in adult cardiomyocytes. When all four of them are combined together, they cause the cardiomyocytes to re-enter the cell cycle and start dividing quickly. They also demonstrated that following heart failure, these combined genes improve cardiac function significantly.

The researchers tested the technique in animal models using cardiomyocytes derived from human stem cells. They stained newly divided cells with a special dye in order to track them; they found that between 15 to 20 percent of the cells divided and remained alive thanks to the four-gene combo. This is a vast improvement on previous studies, which have only managed around 1 percent cell division in adult cardiomyocytes.

The team also made the technique simpler by identifying drugs that could replace two of the four genes involved in the combination. This still produced the same result as using all four genes and is significantly easier, logistically speaking.

Could be used in multiple tissues

As mentioned, the heart is not the only tissue that has cells that either do not divide or do so very slowly. The researchers believe that their technique could also potentially be applied to encourage other tissues and organs to regenerate. This is because the four genes are not unique to the heart and are found in other cells around the body.

If science can unlock the same regeneration in nerve cells, pancreatic cells, and retinal cells, this could be the basis of therapies for heart failure, brain damage, diabetes, blindness, and many other conditions. The good news is these four genes encourage cell division the same way in mice, rats, and human cells.

Conclusion

Manipulating non-dividing cells and returning them to the cell cycle to boost regeneration in organs and tissues holds great potential. Scientists have been working for decades to achieve this in the heart, and now it has been achieved. The next big step is to translate this approach to humans, and we wish them the very best in their future research.

Literature

[1] Mohamed, T. M., Ang, Y. S., Radzinsky, E., Zhou, P., Huang, Y., Elfenbein, A., … & Srivastava, D. (2017). Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration.

Potential New Aging Biomarker in Urine

A potential new biomarker of aging has been discovered by researchers. This substance, found in urine, indicates oxidative damage that could be used to determine how much someone has aged biologically.

Why do we need biomarkers of ageing?

It is important for us to develop accurate and reliable biomarkers of aging, as these can show us how much we have aged biologically rather than chronologically. If we know how we are aging on a biological level, it can help to inform our healthcare strategy.

For example, it might help to predict our risk of developing certain age-related diseases as well as our likely life expectancy. Having this information could allow us to address problems sooner and potentially improve our health and lifespan by making lifestyle changes or starting treatment earlier.

There is an urgent need to develop accurate and cost-effective aging biomarkers in order to determine the efficacy of nascent therapies that target the aging processes; without suitable biomarkers, it will be difficult to prove that something has worked in order to get it approved for public use.

Ideally, a number of reliable biomarkers would be used to create a panel that can accurately assess the efficacy of a treatment. This makes it a must to identify cost-effective and practical aging biomarkers.

Oxidative damage markers

The new study has identified a new potential biomarker that is linked to oxidative damage and could be cost-effectively measured via urine samples[1].

One of the ways in which we age and our cells become damaged is through the action of free radicals. These oxygen byproducts are produced within the cell during normal metabolism. In particular, the mitochondria, the power plants of our cells, create these free radicals as they produce energy.

These free radicals then bounce around the inside of our cells, striking the cellular components and potentially damaging them. A strike to DNA, RNA or mtDNA, for example, can cause damage that leads to cell dysfunction. As we age, our levels of free radicals rise, and so we experience more oxidative damage. This damage then leaves oxidative damage markers, and this is the basis of the research here.

The researchers have identified 8-oxo-7,8-dihydroguanosine as a biomarker that results from oxidation of RNA. In a previous mouse study, the researchers found that 8-oxo-7,8-dihydroguanosine increases in urine with age. So, quite simply, as more oxidative damage is experienced, more 8-oxo-7,8-dihydroguanosine is expressed in urine.

It works in humans too

To test if this also applied to humans, the research team measured 8-oxo-7,8-dihydroguanosine in human urine samples from 1,228 people aged 2 to 90 years old. To do this, they used a very fast testing technique called ultra-high-performance liquid chromatography. Sure enough, they discovered an age-dependent increase of urinary 8-oxo-7,8-dihydroguanosine in people aged 21 years old and over.

The team also noted that the levels of 8-oxo-7,8-dihydroguanosine were similar between men and women, the exception being post-menopausal women, who had a higher level of the biomarker. The researchers believe that this may be due to the decrease in estrogen during menopause, as estrogen is an antioxidant.

Conclusion

8-oxo-7,8-dihydroguanosine could be an effective biomarker of aging, as it is a potentially cost-effective and fast way to determine the biological age of a person. This sort of biomarker is an invaluable tool in anti-aging research.

Literature

[1] Gan, W., Liu, X. L., Yu, T., Zou, Y. G., Li, T. T., Wang, S., … & Cai, J. P. (2018). Urinary 8-oxo-7, 8-dihydroguanosine as a potential biomarker of aging. Frontiers in Aging Neuroscience, 10, 34.

Researchers Discover How to Supercharge Stem Cells

Researchers at the School of Molecular Sciences at Arizona State University have discovered a potential way to supercharge our stem cells and reverse some aspects of cellular aging.

The Hayflick limit

Normal cells cannot divide indefinitely; they have a built-in replicative limit, which is often called the Hayflick limit after its discoverer, Leonard Hayflick. This Hayflick limit means that regular human cells are unable to replicate forever; once they reach their replicative limit, they cease to divide and enter senescence, a nondividing state in which the cell destroys itself.

The Hayflick limit is directly related to the length of DNA repeats found on the ends of the chromosomes. These repeats form protective cap-like structures called telomeres, which protect the chromosomes from DNA mutations that can cause the genome to become unstable.

Every time a cell divides and makes a copy of itself, the telomeres shrink in size until they become so short that they cannot protect the chromosome ends. This continual telomere attrition is thought to be one of the reasons we age and acts like a “molecular clock” that counts down the replicative limit of cells. The loss of replicative potential in our cells is linked to the aging process, with reduced cell populations directly leading to the loss of tissue and organ function observed during aging.

A molecular fountain of youth

The enzyme telomerase helps to counteract telomere attrition by adding more DNA repeats to the caps, effectively rewinding the molecular clock to increase the lifespan of a cell and its potential to replicate. Some cells do produce telomerase, but most of our cells do not.

Our regular somatic cells do not produce telomerase, but this is not a problem because we want them to reach their replicative limit and destroy themselves via apoptosis, a programmed cell death process, once they reach their Hayflick limit. This is because aged cells may have picked up mutations during their lives, so keeping aged and potentially damaged cells alive and replicating is an invitation for cancer to develop.

The problem is that this steady loss of telomeres also affects our stem cells; these master cells can become various other types of cells, and they supply tissues with the cells they need to remain healthy. Stem cells combat telomere loss by producing telomerase, but this only serves to slow down the molecular clock and does not immortalize these cells. Stem cells are also better at repairing themselves than somatic cells.

Once stem cells start getting critically short telomeres, they also stop dividing and cannot replenish our organs and tissues. This causes another aging process, stem cell depletion, and leads to organ failure, poor tissue healing, and loss of tissue function.

Supercharging our stem cells

Understanding the underlying mechanisms of telomerase and replicative limits holds the potential to reverse telomere attrition and thus an important part of cellular aging. This has implications for preventing or reversing age-related diseases and potentially allowing us to live longer in good health.

The new study has discovered a critical step in the telomerase enzyme catalytic cycle; this cycle determines the ability of the telomerase enzyme to create extra DNA repeats on chromosome ends and thus maintain the telomeres[1].

The researchers show that telomerase has a kind of “braking system” that ensures the proper synthesis of DNA repeats. However, this brake also limits the overall activity of the telomerase enzyme, and finding a way to release this brake safely holds the potential to effectively restore lost telomere length in stem cells, partially reversing cellular aging and allowing tissue regeneration and the supply of fresh cells to continue.

The researchers demonstrate that this braking system relates to a pause signal that is encoded in the RNA template of telomerase. This means that once it has created a ‘GGTTAG’ repeat sequence, it pauses; when the next sequence is started and DNA synthesis begins again, this pause signal remains active and limits DNA synthesis.

This discovery also explains why a single specific nucleotide stimulates telomerase activity, solving a mystery that has eluded scientists for decades. In effect, this means that by specifically targeting the pause signal and turning it off, we remove its ability to interfere with repeat DNA synthesis. In effect, we could use this discovery to effectively supercharge telomerase, making it more efficient at replacing lost DNA repeats at a faster rate and thus keep pace with loss to a higher degree. This has the potential to rejuvenate our aging stem cells and keep our organs and tissues supplied with vital replacement cells.

It also has implications for treating various diseases that are linked to impaired telomerase activity, such as dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis.

Walk the line

While a therapy that targets this pause mechanism could partially reverse cellular aging and thereby prevent some age-related diseases, it would need to be carefully balanced. Too much of a good thing can be harmful, so a therapy would need to be carefully calibrated to maintain efficient cell regeneration without allowing unchecked cell proliferation. Essentially, we would be walking the line between highly efficient cell rejuvenation and tissue regeneration, and increased cancer risk.

The key is targeting the right cells. Somatic cells make up the majority of the cells in our bodies, and as mentioned previously, they do not produce telomerase, meaning that as they divide, they reach their Hayflick limit far sooner. This lack of telomerase activity in somatic cells is a mechanism that reduces the risk of cancer. Telomerase production is what most cancers use to fuel their rampant, uncontrolled growth, so it is a good thing that the ability to produce telomerase is turned off in our somatic cells.

The risk is that drugs that non-selectively increase telomerase activity in both stem cells and somatic cells are potentially dangerous. The researchers’ goal is to enhance telomerase activity and the production of DNA repeats selectively in stem cells while avoiding doing so in somatic cells.

The next step is to screen or design small-molecule drugs that can specifically target stem cells, turning off this pause mechanic as a path to therapies that address age-related diseases and help to restore youthful tissue and organ function to aged people.

Conclusion

Hopefully, we can find a way to walk the line between cancer and enhanced tissue regeneration; after all, a number of species already do, as do we during early development. The usual caveats apply here, this is only initial in vitro data and an in vivo study will need to follow to see if it is effective. Should this pan out then it has the potential to treat various age-related diseases, and that will be very welcome news indeed!

Literature

[1] Chen, Y., J.D. Podlevsky, D. Logeswaran and J.J.-L. Chen (2018). A single nucleotide incorporation step limits human telomerase repeat addition activity. EMBO. J. 37: e97953, DOI 10.15252/emboj.201797953.

Caloric Restriction Improves Regeneration in Intestines

Caloric restriction has long been known to increase the lifespan and healthspan of most studied animals. Research also shows that animals given a calorie-restricted diet are also generally more able to regenerate tissue damage following injury.

Caloric restriction improves tissue regeneration

A new study by the Lengner lab at the University of Pennsylvania has identified the actual cells responsible for this increased regenerative capacity in intestinal tissue[1]. The researchers found that when a mouse given a calorie-restricted diet is exposed to radiation, a specialized type of stem cell known as a reserve stem cell is able to survive and rapidly repair intestinal tissues.

Numerous studies have shown that caloric restriction, while unpleasant, can improve healthspan and reduce the risk of diabetes, heart attack, and some other age-related diseases. Studies also show that caloric restriction allows animals to regenerate injured tissues more efficiently.

However, the effects of caloric restriction are really beyond debate, given the amount of supporting data. What was not clear was the molecular and cellular basis for the observed health benefits.

It had been proposed that caloric restriction works and increases tissue repair by influencing the activity of stem cells. These are tissue-resident stem cells that change into the various cell types of their native tissues. The research team had previously explored how some stem cells in the intestines resist DNA damage and the reasons that caloric restriction might be influencing these stem cells to resist damage.

They had reviewed recent studies that looked at the effects of caloric restriction on the active intestinal stem cells commonly found in this tissue. These active stem cells are the workhorses of the tissue, creating the high turnover of cells needed in this environment, but they are also easily damaged by radiation exposure. The researchers, therefore, felt it was unlikely to be the intestinal stem cells that were responsible for the increased regeneration that caloric restriction provokes.

Reserve stem cells to the rescue

Their attention moved to another type of stem cell found in the intestinal tissue, the reserve stem cell. In a previous study, the team had demonstrated that these particular stem cells are generally in a dormant state and remain well protected from radiation and similar insults, such as chemotherapy. They found that these dormant stem cells become activated when serious injury kills the active stem cells in the tissue; once this happens, the reserve stem cells go into high gear and start to repair the tissue. So, the researchers proposed that these cells were responsible for the regenerative effects of caloric restriction.

In order to test this, the team looked at how these specialized intestinal stem cells responded to caloric restriction in mice and when exposed to insult from radiation.

The mice were given a diet that was 40 percent lower in calories than a regular diet; the researchers saw that the reserve stem cells expanded by a five-fold ratio after becoming increasingly active. Additionally, the team found that selectively removing these cells from mice cut their regenerative capacity in half in the intestinal tissue. This suggests that reserve stem cells play a key role in tissue repair and regeneration and that caloric restriction boosts their activity.

Next, the researchers honed in on the exact mechanisms through which these cells were acting, and to do so, they compared the gene expression of normal mice versus calorie-restricted mice. They found that the reserve stem cells suppressed various pathways known to be regulated by the nutrient-sensing complex mTOR (mammalian target of rapamycin).

The mTOR pathway is one of the four pathways that control metabolism and is known to influence aging; this is part of deregulated nutrient sensing, a hallmark of aging. Other studies show that activating mTOR can mobilize dormant stem cells, which is needed in order for tissue to be regenerated, as it serves as a wake-up call.

The researchers here discovered that reserve stem cells had low mTOR activity, which became even lower during caloric restriction. Also, lower mTOR activity correlates with better resistance to injury. However, if the tissue needs to regenerate after an injury, the reserve stem cells would need mTOR. Strangely, they found that when injured, the calorie-restricted mice could activate mTOR better than the control mice.

This suggests that even though mTOR is initially suppressed by the reserve stem cells, it is also more readily activated in calorie-restricted mice following injury. Why this happens is not yet known, but the researchers intend to find out in a follow-up study.

Finally, the research team tested leucine, an amino acid that activates mTOR, and rapamycin, a drug known to inhibit mTOR activity. They wanted to find out if mTOR regulated the activity of reserve stem cells and found that stem cells proliferate when exposed to leucine and were inhibited when exposed to rapamycin.

The researchers found that on one hand, leucine made reserve stem cells more vulnerable to radiation and less able to regenerate tissue damage following radiation injury. On the other hand, they found that rapamycin protected the reserve stem cells from radiation by keeping them dormant.

The mTOR pathway and its seemingly paradoxical role here poses an intriguing puzzle and as their next step, the researchers plan to look beyond nutrient sensing to see what type of signalling molecules can encourage the activation of reserve stem cells. It seems that keeping mTOR levels lower supports longevity, but that there is a fine balance between keeping it low but allowing it to be expressed when required during injury.

A word of caution

It should be pointed out that this experiment was in mice, but the health benefits do appear to translate to humans, as various studies show. Unfortunately, while mice do live considerably longer when on caloric restriction, this increase in lifespan is not seen in humans.

Broadly, caloric restriction is beneficial to humans, so it is still worth considering, and other studies suggest that this improved regeneration is also seen in other tissues. There are also some people who might think that rapamycin may be a way to have your cake and eat it.

However, we should be cautious here. Rapamycin is not a suitable replacement for caloric restriction, as its effects are long-lasting and would continue to prevent stem cell activation following injury; this would lead to poor tissue regeneration, as reserve stem cells would not be mobilized effectively. While rapamycin and caloric restriction do share some common targets, they are not the same.

Like rapamycin, caloric restriction does inhibit mTOR but, as this experiment shows, can be easily reversed as a response to injury. This is not the case with rapamycin, which remains in the system and continues to inhibit mTOR regardless of injury and thus reduces the regeneration of tissue.

Conclusion

Sorry, folks; for the time being, there is no pill to mimic the effects of caloric restriction, so if you want the health benefits, cutting your calories is currently the only way to go.

Literature

[1] Yousefi M, Langner C (2018). Calorie Restriction Governs Intestinal Epithelial Regeneration through Cell-Autonomous Regulation of mTORC1 in Reserve Stem Cells.Stem cell reports 10.1016/j.stemcr.2018.01.026

FDA RMAT Framework is Win-Win for Gene Therapies

Back in November 2017, the FDA announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies. Both draft guidance documents had 90-day comment periods, and we at LEAF joined forces with the Niskanen Center to submit comments to the FDA to ensure that the voice of the community for healthy life extension was heard. These new regulations could have considerable implications for the therapies and technologies being developed as part of the biomedical gerontology field.

The first draft guidance addresses how the FDA intends to optimize its regulatory requirements for devices used in the recovery, isolation, and delivery of RMATs (regenerative medicine advanced therapies), including combination products.

The second document explains what expedited programs may be available to sponsors of regenerative medicine therapies and describes what therapies may be eligible for RMAT designation.

According to new FDA regulations, a drug is eligible for designation as an RMAT if:

  • The drug is a regenerative medicine therapy, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, except for those regulated solely under Section 361 of the Public Health Service Act and part 1271 of Title 21, Code of Federal Regulations;
  • The drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and
  • Preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition

We hope that this joint project will support the improvement of US regulations that concern these innovative treatments and will make the overall regulatory landscape more friendly. Below, we cite the most important notes from our resulting paper.

Last week, the Niskanen Center joined with the Lifespan Extension Advocacy Foundation in filing comments to the Food and Drug Administration (FDA), offering our support for the agency’s new regenerative medicine advanced therapy (RMAT) designation draft guidance for industry. Although there are opportunities for marginal improvements to the guidance, and FDA approval processes more generally, we are happy to see that the agency chose to include gene therapies in its interpretation of what qualifies as a regenerative medicine therapy. Under section 3033 of the 21st Century Cures Act, the FDA was tasked with developing an accelerated approval process for regenerative advanced therapies. Such therapies would qualify for expedited review and approval so long as the drug (a) met the definition of a regenerative medicine therapy, (b) was “intended to treat, modify, reverse, or cure a serious condition,” and (c) “has the potential to address unmet medical needs” for a serious disease or condition. Unfortunately, the bill’s definition of a regenerative medicine advanced therapy was unclear on whether gene therapies, in particular, would qualify. Luckily, the FDA clarified this point. As the RMAT guidance document notes: gene therapies, including genetically modified cells, that lead to a durable modification of cells or tissues may meet the definition of a regenerative medicine therapy. Additionally, a combination product (biologic-device, biologic-drug, or biologic-device-drug) can be eligible for RMAT designation when the biological product component provides the greatest contribution to the overall intended therapeutic effects of the combination product. This is an excellent development and one that portends immense benefits for future gene therapy applications submitted for FDA approval. According to the guidance, the new RMAT designation, unlike other fast-track approval and review processes, “does not require evidence to indicate that the drug may offer a substantial improvement over available therapies.” Liberalizing the threshold standards of evidence for RMAT designation ensures that future gene therapies will encounter fewer unnecessary roadblocks in delivering more effective and innovative treatments for individuals suffering from debilitating diseases. As we note in our concluding remarks: Overall, we consider the RMAT guidance to be a stellar improvement over other expedited programs, especially in its qualifying criteria. However, greater clarity is needed in order to capture the benefits of more advanced cell therapies that can help contribute to the healthy aging and well-being of American citizens. As FDA Commissioner Scott Gottlieb recently noted: “The benefits of [gene therapy] science—and the products that become available—are likely to accelerate. How we define the modern framework for safely advancing these opportunities will determine whether we’re able to fully realize the benefits that these new technologies can offer.” We agree wholeheartedly. Developing a regulatory framework that accommodates safety and innovation will be a key determinant of how quickly the benefits of regenerative medicine, gene therapy, and anti-aging research revolutionize the lives of Americans. This guidance is an important and promising step in the right direction. With the right modifications, it can help usher in a new age of healthcare improvement for individuals from all walks of life.

You can also read and download the full comments submitted to the FDA here.

Dentists May Soon Regenerate Teeth Using GSK3 Antagonists

What if I told you that we could regenerate our teeth? Well, that may soon be a possibility thanks to new research showing that teeth can be encouraged to regrow. Rather than drilling holes into teeth and plugging them with artificial fillers, dentists in the near future may be able to rebuild your teeth with a new technique.

Stimulating stem cells

Professor Paul Sharpe, a scientist based at King’s College in London, and his team have found a way to do just this in mice. They published a study last year that described this new approach[1].

The researchers wanted to increase the natural ability of teeth to repair themselves by activating the stem cells that reside in the dental pulp of teeth. They knew that previous research showed that the wnt signaling pathway is a key pathway for stem cell activity in many parts of the body, and they wanted to see if it works the same way in teeth.

The researchers believed by that using drugs to stimulate the wnt pathway, they could increase stem cell activity in teeth and boost their regenerative potential significantly. Normally, this level of regeneration is only seen in animals like starfish and salamanders, but the researchers wanted to see if we can benefit from the same regenerative capacity.

To see if this would work, the team drilled holes into the molar teeth of mice to simulate dental cavities. Next, they exposed collagen sponges (the same protein found in the dentin in teeth) to a variety of drugs known to stimulate the wnt pathway. Then, they placed these sponges into the cavities and sealed them in for between 4 to 6 weeks.

After this time, the researchers saw that the teeth exposed to these sponges had created a lot more dentin than the control mice and mice given typical dental fillers. The researchers observed that this was essentially a full repair and, in most cases, the teeth of the mice were as good as new.

The next step towards clinical trials

Since then, the researchers have tested the technique on rats, which have considerably larger teeth than mice, making them the logical next step. The research team report that the therapy worked equally well on the rats as it did in the mice in the original study; however, the data is yet to be published.

The researchers are now screening their drug candidates to identify the most effective of the wnt-stimulating drugs. They are also adapting the technique to work with modern dental practices by injecting a gel containing the drug into a dental cavity and hardening it using a UV light to seal it in. This is similar to how dentists currently seal and repair teeth, so this technique would be easy to incorporate into dental practice.

Literature

It will be several years before this enters human clinical trials, but the results so far are promising, and the process may be quicker than normal because a number of the candidate drugs are already approved for human use. The arrival of this technique will revolutionize dentistry and is a great step forward for regenerative medicine in general.

Such techniques have the potential to translate to other tissues to help encourage regeneration, so it is also relevant to aging research. We look forward to more developments from this team in the future.

References

[1] Neves, V. C., Babb, R., Chandrasekaran, D., & Sharpe, P. T. (2017). Promotion of natural tooth repair by small molecule GSK3 antagonists. Scientific reports, 7, 39654.

Treating Aging as a Disease

Aging and cancer are closely linked, with the latter being, more often than not, a consequence of the former. Cancer is caused by the aging hallmark of genomic instability, and the two are intertwined. While it is true that young people can get cancer, it is a disease that generally affects older people; indeed, beyond 60, the risk of cancer rises greatly.

Society often talks about the search for a cure for cancer but rarely considers the root of that disease: the genomic damage that gives rise to uncontrollable cell division and the immortalization of mutant cells. It is therefore quite irrational that some people consider cancer to be a disease but rarely accept that the aging processes behind it are also pathological and could potentially be directly treated to prevent cancer in the first place. These processes are not given disease names, but they drive pathology and the appearance of disease. We explore this topic in more detail here.

Ten years ago, the idea that aging might be treated just the same way as a disease was often the subject of ridicule and mockery; however, things have definitely changed since then. More recently, journalists have taken the topic more seriously, there are more articles exploring the subject, and, on the whole, the level of mockery has fallen. This is likely no surprise to those of you who have been following the field for more than a few years, given its increases in funding, investment, and scientific publications.

“If you can control both the environment and the genetics, you can get people that live youthful healthy lives for exceptionally much longer than others. In industrialised nations, most of the diseases are due to age-related diseases and I think those too can be handled.” – Professor George Church

A great example of this change is the number of popular-media articles that have appeared in the last year or two about clearing senescent cells using senolytics. This is excellent news because senolytics are a true repair-based approach to aging and are now being developed by several companies with serious investment behind them.

“We want to fix the things we don’t like about the changes that happen between the age of 30 and the age of 70” ­- Aubrey De Grey

The ambitious quest to cure aging like a disease

Today, I would like to draw your attention to an article in the BBC, which, in all fairness, is pretty comprehensive in its discussion of the field. It is also nice to note that, in general, this article is also positive about the prospect of doing something about aging.

Of course, no discussion about the potential of a future free from age-related diseases would be complete with the other side of the coin. More often than not, journalists feel almost compelled to include a counterpoint to people advocating for healthier and longer lives through science and technology. The tired old arguments are frequently included for the sake of balance, including the idea that we should just accept aging and suffering as natural and not try to do something about it.

Extending human lifespans by decades or even hundreds of years will present us with some difficult social realities. As BBC Future has explored before, there could be major societal impacts if we all start living longer. There are some that fear greater longevity could lead to swelling populations and raise doubts that our planet could support such numbers.

I am happy to see that such concerns do not dominate this article and that the actual science, progress, and figures working in the field are given more of the spotlight. There is almost no doubt that these disruptive technologies will create challenges for society, but, by the same token, I am confident that, as a society, we will adapt to them and create a better world as a result. Of course, experiencing challenges and finding solutions to them is what mankind has been doing since we first formed societies, and the arrival of rejuvenation biotechnology will be no exception to this rule.

Conclusion

It is refreshing to see a more positive portrayal of the field, especially in such high-profile media as the BBC. More of these kinds of articles are sure to follow as we draw ever closer to the arrival of the technology that could potentially end age-related diseases. A healthy, long life, free from the diseases of old age, is the kind of future that people working in this field want, and hopefully, the greater portion of society will soon agree with us.

A Potential Blood Test for Alzheimer’s Disease

A simple technique to measure the amount of amyloid beta in the brain could improve diagnosis and drug trials for Alzheimer’s disease, according to the results of new research.

A simple blood test

Japanese researchers led by Dr. Katsuhiko Yanagisawa have published a new study suggesting that a screening test could help to boost the success rate of Alzheimer’s drug research. The research team has shown that a simple blood test can accurately measure the amount of amyloid beta, a protein that appears in the early stages of Alzheimer’s disease.

Amyloid is a typical pathological feature of Alzheimer’s disease, so being able to discern how much amyloid is present is key when designing optimal clinical trials. Currently, the only way to measure amyloid accumulation in a living person is either via an expensive positron emission tomography imaging (PET scan) or by taking a sample of cerebrospinal fluid (CSF) via a lumbar puncture, or spinal tap. A blood test would be a far less invasive and costly procedure to help determine how much amyloid is present in a patient.

The researchers believe that suficient amounts of amyloid beta penetrate the blood-brain barrier and enter the bloodstream to be a reliable measure of cognitive function. The hope is to replace the current, costly analysis methods with a simple, cost-effective way to detect preclinical Alzheimer’s and disease progression while improving clinical trials.

In order to measure the amyloid present in the bloodstream, the research team used a technique known as immunoprecipitation with mass spectrometry, which uses antibodies to bind to target proteins. The study included 121 people from Japan and 252 from Australia; of this group, there were people with normal brain function, mild cognitive impairment and Alzheimer’s disease.

The researchers noted that the amount of amyloid present in the bloodstream correlated directly with the level of cognitive impairment. The level of blood amyloid also correlated with results from PET scans and spinal fluid samples from the same patients; this confirms that the blood test is effective.

The researchers are now continuing their study and expanding it in the hopes that they can bring an amyloid blood test closer to standard clinical use.

Conclusion

Having a reliable, non-invasive, and cost-effective biomarker for Alzheimer’s disease is a great result for clinical trials and drug development and may even find utility with home users who wish to monitor their health. We wish the researchers the best of luck and hope that soon, this test will be accepted as standard medical practice.

Literature

[1] Akinori Nakamura, Naoki Kaneko, Victor L. Villemagne, Takashi Kato, James Doecke, Vincent Doré, Chris Fowler, Qiao-Xin Li, Ralph Martins, Christopher Rowe, Taisuke Tomita, Katsumi Matsuzaki, Kenji Ishii, Kazunari Ishii, Yutaka Arahata, Shinichi Iwamoto, Kengo Ito, Koichi Tanaka, Colin L. Masters & Katsuhiko Yanagisawa (2018). High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature doi:10.1038/nature25456

Skulls

The Misconception of the Two Deaths

When we talk about life extension, we mean people living much longer than they do now, and, more importantly, people who are healthier for longer. For example, we mean being 120 with the health of a 30-year-old. Hang on, though—hasn’t a person who is 120 years old already more than lived their life? Hasn’t that person’s time more than come?

News flash: you haven’t lived your life until you’re dead, and even then, you might not necessarily have crossed off all the items on your list. So, no, there is no such thing as an age when you have, by definition, “already lived your life”—not 80, 90, 100, nor any other. What people actually mean when they say that someone has “already lived their life” is that, in their opinion, that person has lived long enough, and thus he or she might as well, and perhaps even should, die.

People who, for one reason or another, fear a world without aging tend to say things like that. Personally, I am much more afraid of a world where other people get to tell you when your life has been long enough, and, consequently, I tend to say that the only one who should have the right to decide when you’ve lived long enough, if ever, is you—not other people, not nature, not an imaginary greater good. You.

However, I don’t think that these people just like telling others how long they should live; rather, it is my opinion that they fall prey to a common misconception, which I like to call the misconception of the two deaths.

How many kinds of death are there? Well, as a first approximation, you might be tempted to answer “two”; there is death by old age, and then there are other causes. (In case you’re wondering, these are exactly the two deaths that give the misconception its name, so, as you might guess, this answer is wrong.) Then, if one wants to be pedantic, one could start listing examples of the other causes, and thus the answer might easily become “many”. This is wrong too, by the way.

The correct answer is one. There is only one kind of death, namely death by “something essential in your body stopped working.” Then, of course, we can go into details, such as what specifically stopped working and why, but they’re indeed just details, useful mainly to any doctors who were trying to prevent your death or to the coroner to write on your death certificate.

Let me give you an example. Suppose I got shot in the heart. (Hopefully that won’t happen.) What killed me would be the fact my heart stopped; in turn, what caused my heart to stop was the bleeding hole that the gunshot punched into it. Similarly, if I died of a heart attack, the cause of death would still be that my heart stopped, but what caused it to stop would be something else—probably, I read a pro-aging article or something like that.

So, when people say that someone has died of old age, they’re just using shorthand to say that something essential in that person’s body stopped working, and the cause of that failure was something that has a higher likelihood to happen to you past age 70 or so.

What does this have to do with the whole issue of whether somebody has already lived their life or not? In my opinion—and, mind you, it’s just my opinion that we’re talking about—it has everything to do with it. I think that many people assume that all the deaths in the “other causes” category are not okay in the sense that, when you die of one of those, you have not yet lived your life; conversely, when you die of old age, they think you have. Probably, it’s because they think that the so-called death by old age:

  1. happens of its own accord, without external intervention;
  2. lets you live for as long as “naturally” possible;
  3. generally allows sufficient time for you to do all that is considered standard for human life (study, work, have a family, etc.);
  4. occurs at a point when you’re generally not healthy enough to do much else;
  5. is inevitable, which adds to the feeling that this is how it ought to be.

Point number one is only partially true. Sure enough, even with the healthiest of lifestyles, human genetics is such that you can’t really hope to live much more than 120 years (without more radical interventions, such as rejuvenation biotech). However, sufficiently unhealthy lifestyles can make the very same diseases of old age happen sooner. This means that the way you live your life affects how long your life will be; therefore, it’s not true that death by old age only happens of its own accord. Your external interventions, even something as relatively trivial as what you eat, can and do make a difference.

Consequently, point number two is not true. Even without opening the worm can of the meaning of “natural”, since the age at which the diseases of aging strike (and thus kill) you is influenced by your actions, it is by no means guaranteed that you couldn’t have lived longer than you did if only you had made different lifestyle choices, even something as simple as eating in a more healthy way.

Points three and four are the truly interesting ones here. Currently, the life of an average human entails a number of standard milestones whose achievement pretty much defines how much of a successful, or at least “normal”, life one has lived. We’re talking mainly about studying, having a career, starting a family, perhaps becoming good at any hobbies you might have, having grandkids, and then “enjoying” your “golden years”.

These milestones dictate the rhythm of our lives to such an extent that not only do people cast suspicious glances at you when you fail to deliver on schedule (“You’re thirty already; when are you going to have kids?”, “Isn’t it about time you settled down and had a career?”, etc); but also, most people think that, once these goals are accomplished, there wouldn’t be much else to look forward to even if you were healthy enough to accomplish more, and as per point four, you’re not anyway.

These two points are pretty much the very essence of this whole “having already lived one’s life” thing; past the standard milestones, there isn’t anything else worth doing, and even if there was, you’re in no condition to do it. Hence, you’ve pretty much already lived your life. One might even think that human lifespan is just long enough to let us do precisely all we want or need to do.

This is completely backwards, of course. Human lifespan didn’t stretch and shrink just enough to perfectly accommodate our favourite milestones. Rather, we adapted to our lifespan, planning and scheduling our lives, our societies, and our policies around our biological limitations. Our standard milestones and their chronological progression are a consequence of our average healthspan and lifespan, not vice versa. The “normal” course of life outlined above is by no means the right one, better than others, or what ought to be. It’s just all we could afford under the circumstances. For some people, it might be enough; for others, it might be terribly insufficient. However, I do think that, given the option, many people who profess their satisfaction with the current state of affairs might seriously reconsider.

This brings us to point five, which, up until this moment in history, has made the whole discussion moot; whether it occurs sooner or later, death by old age is inevitable. So, not only is there little point discussing ifs and buts, but maybe, if things stand the way they do, there’s a good reason. Isn’t it comforting to think that, if we’re all doomed to die, there’s a good reason why this is so? Pretty much the way that a fervent believer may not understand why God let so many innocents die in a terrorist attack, or a war, or a catastrophe, but is relieved to think He must have had a good reason to do so, many people think old age comes to take us away for some higher purpose—preventing overpopulation, boredom, or whatever.

With the advent of pioneering rejuvenation biotechnology, the inevitability paradigm of point five is starting to crack, and as it will become clearer and clearer that defeating aging is possible, I argue that many people will do away with the idea that if aging exists, then it ought to, without even bothering going through the (obvious) reasons why this idea is fallacious. The previous four points, as we’ve seen, rest on seriously shaky grounds, and taken all together, these points don’t make death by old age any more acceptable than any other kind of death, and don’t mean in any way that when you die of aging, you had already lived your life and couldn’t—or shouldn’t—ask for more.

Who knows; maybe, there will come a point when you’ve already lived your life. However, when that point is, and whether and how your life should end, I think should be only in your hands.

Could Klotho Treat Dementia by Targeting Aging Itself?

Researcher Dr. Dena Dubal, from the University of California San Francisco, is considering a new approach to combat neurodegenerative diseases, such as Alzheimer’s disease and dementia, using a protein known as klotho.

Aging is the foundation of age-related diseases

Instead of trying to understand each of these diseases and the complex mechanisms unique to both, she considered what all these conditions have in common; the answer, of course, is aging.

Like all age-related diseases, these conditions develop because of the aging processes that damage us and prevent our bodies from repairing themselves effectively. These processes have been defined clearly in the Hallmarks of Aging, which divides aging into a series of processes and offers potential solutions to each[1].

Aging is the greatest risk factor for neurodegenerative diseases and one of the greatest challenges that the biomedical field faces. Dr. Dubal believes that our current understanding of aging could help us to combat neurodegenerative diseases. She asks, “Why don’t we just block aging?” In other words, she suggests targeting the aging processes to potentially halt multiple age-related diseases.

From Greek myth to modern science

With this in mind, she got interested in a protein called klotho, which is named after the Greek legend of Clotho, a mythological figure who created the thread of life and had control over when gods and mortals would die.

The klotho protein was originally documented in 1997 by researchers in Japan[2]. During this study, they also discovered the suppressive role that klotho has against some aspects of the aging process. They also learned that defective klotho gene expression in mice results in a syndrome similar to human aging, including a shorter lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis and emphysema.

It was later discovered that transgenic mice that produce more klotho live longer [3-4]. This was also confirmed in humans, as people who produce more klotho tend to live longer than people who produce less.

The klotho protein functions as a circulating hormone that binds to a cell-surface receptor and suppresses the intracellular signals of insulin and insulin-like growth factor 1 (IGF1); it is an evolutionarily conserved mechanism for extending lifespan. Klotho influences part of the aging hallmark known as deregulated nutrient sensing, one of the reasons we age.

Klotho is neuroprotective

Back in 2014, Dr. Dubal wanted to find out if klotho levels help our brains remain healthier as we age and reduce the impact of cognitive decline. She and her research team discovered that in both mice and humans, more klotho means better cognition, meaning that it is neuroprotective[5].

In humans, only around 20 percent of people have high levels of klotho, but Dr. Dubal wants everyone to benefit from its neuroprotective effect. Her research team wants to test the potential of klotho as a neuroprotective therapy.

The klotho protein exists in two distinct forms; the first is anchored in the cell membranes of the organs, mostly in the brain and kidneys, and the second form is seen when the protein becomes detached from its anchor and then floats around the bloodstream.

Dr. Dubal’s team discovered that they could simply inject this second form of the protein directly into mice and receive the same effect that genetically high klotho levels have.

Perhaps even more impressive was that the mice treated showed improved brain function within just four hours, and this treatment worked in young mice, old mice and an Alzheimer’s mouse model.

The next step for Dr. Dubal and her team will be to work out how klotho interacts with the brain without it crossing the blood-brain barrier. Once this information is discovered, it could then lead to a klotho therapy for humans to improve cognitive function and protect the brain from age-related diseases.

In a University of California San Francisco article, Dr. Dubal said, “For humans, the end game really is: how can we increase our ‘healthspan?’” She continues, “And that may go hand in hand with an increase in lifespan, because the things that help us to live longer are also the things that help us to live better.”

Conclusion

Once again, it is good to see respected researchers talking about combating age-related diseases by targeting the aging processes themselves. This approach has the potential for treating or preventing multiple diseases at once, and it is a shift in thinking that the medical industry is starting to accept. The sooner the majority of researchers take this approach, the sooner we can start to really do something about age-related diseases.

A therapy that influences deregulated nutrient sensing is an interesting prospect and may lead to a viable neuroprotective therapy if a simple injection works on humans the way it does on mice.

Literature

[1] López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194-1217.

[2] Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., … & Iwasaki, H. (1997). Mutation of the mouse klotho gene leads to a syndrome resembling ageing. nature, 390(6655), 45.

[3] Kurosu, H., Yamamoto, M., Clark, J. D., Pastor, J. V., Nandi, A., Gurnani, P., … & Shimomura, I. (2005). Suppression of aging in mice by the hormone Klotho. Science, 309(5742), 1829-1833.

[4] Dubal, D. B., Zhu, L., Sanchez, P. E., Worden, K., Broestl, L., Johnson, E., … & Kuro-o, M. (2015). Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. Journal of Neuroscience, 35(6), 2358-2371.

[5] Dubal, D. B., Yokoyama, J. S., Zhu, L., Broestl, L., Worden, K., Wang, D., … & Ho, K. (2014). Life extension factor klotho enhances cognition. Cell reports, 7(4), 1065-1076.

Rejuvenation Roundup January 2018

The first month of the new year is already behind us, so it is time to sit down and look back at what happened in the rejuvenation world during January; thankfully, there’s plenty of good news to talk about!

Healthy aging is back in WHO’s agenda

You might recall that late last year, LEAF board director Elena Milova wrote about our concerns about WHO’s decision to leave out healthy aging out of its draft programme of work 2019-2023. Luckily, thanks to the efforts of the longevity community, this danger has been averted; as we mentioned in the December 2017 roundup, the vast majority of the feedback that WHO has received through the open consultation on its programme stressed the importance of including aging in the draft. As a result, WHO revised its draft, which now includes several provisions on healthy aging, as discussed here. This is a great achievement of all longevity activists and proves that we can have an influence on public opinion and policymakers. We’d like to thank each and every person who helped us get there!

Record-smashing funds for SENS Research Foundation

You probably recall our excitement last December about the $1 million bitcoin donation made by the anonymous donor running the Pineapple Fund, which pushed SRF’s winter fundraiser well beyond its initial $250,000 goal. You can imagine our (and SRF’s!) amazement when we found out that their digital-currency good fortune didn’t stop there; one more million dollars in bitcoin was donated to SRF by another anonymous donor, and another $2.4 million in Ether were donated by Vitalik Buterin, the cofounder of Ethereum and Bitcoin Magazine. Together with the other winter fundraiser donations, this amounted to a whopping $5,041,134, which makes for a fantastic (late) Christmas present for SRF!

We’re not done congratulating them yet, because SRF was also one of the winning charities of Project4Awesome 2017, as officially announced by John Green in this video. LEAF was not among the winners of this year, but we’re nonetheless extremely happy and excited about the huge increase in popularity of life extension and the large exposure the movement as a whole is gaining!

A digest of articles from FA!

In this article, veteran rejuvenation advocate Reason of the blog Fight Aging! discusses a study suggesting that there comes a point in middle age when exercising cannot reverse the adverse effects of a sedentary life any longer. While exercising yields benefits at any age, and in this sense it’s never too late to get off the couch, some aspects of secondary cardiac aging—that is, consequences of external factors that negatively affect your heart—won’t be undone by exercising when it’s too late. Still, you should always exercise if you can in order to slow down health deterioration.

While most of the damage occurring to our DNA is quickly taken care of by efficient repairing mechanisms, some damage slips through the cracks and manages to accumulate over time. Some of this damage may lead to cancer, but does the rest of the damage matter for aging? Here, FA! points out a paper that puts more weight on the degree to which such damage is replicated, rather than just its occurrence.

LEAF news

In case you haven’t been following the blog too closely lately, here’s a selection of our articles that you may want to go back to have a look at.

Volunteer writer and biomolecular engineer Ariah Mackie discussed deregulated nutrient sensing—one of the hallmarks of aging—in this article. If you want to deepen your understanding of the biology of aging, you should check this one out!

In occasion of his birthday, LEAF President Keith Comito made a present to the life extension community—a video to recap our achievements of the past year and whet our appetite for what’s to come in 2018.

If you’re still among those who are undecided between aging as natural or a condition to be treated, this article by Steve Hill may solve your conundrum, explaining how aging is actually both.

We interviewed Drs. Michael and Irina Conboy on the topic of parabiosis to shed some light on what rejuvenative benefits we can expect from filtering old blood.

The biotech Valley of Death

The folks at Geroscience wrote about something I’ve often noticed myself and surely you have too; all too often, we hear about some new, thrilling biomedical breakthrough only to never hear about it again. This may induce people to remain skeptical about, and at times even show contempt for, research news. (If you’re a Reddit user, you are probably accustomed to cynical comments along the lines of “here’s Reddit’s weekly cure for cancer” on any news on cancer discoveries, for example.) In this video interview, Geroscience’s lead editor Tegan McCaslin and venture capitalist James Peyer discuss what happens when new discoveries reach the “biotech Valley of Death” and the hurdles that make it difficult to leave that dreadful place.

Coming next month

Altered Carbon premiere screening

On February 2, we will host the premiere of the new Netflix series Altered Carbon, showcasing the dark and dangerous world of Takeshi Kovachs, where only the wealthy can re-upload their digitized selves from one clone to another forever. You can have a look at the series’ trailer here.

SENS Research Foundation’s CSO Dr. Aubrey de Grey will be attending the event and hold a Q&A session right before the show. We will also be offering themed drinks and snacks, and there’ll be a chance to mingle with other fans of the series, so don’t miss out! You can find more information and get your tickets here. The event’s revenue will go towards supporting LEAF/Lifespan.io.

AI vs Aging panel

In occasion of the late longevity record holder Mme Jeanne Calment‘s birthday, on February 21, we will host a panel with the MouseAge team on the topic of artificial intelligence in aging research—more details to come. On the same day, due to a suggestion by LEAF volunteer Victor Bjoerk, The Longevity Reporter will host a Facebook event where all participants are invited to show their support for aging research by taking a selfie with Mme Calment’s favourite foods—chocolate and olive oil.

Two Journal Clubs in February

It is our custom to have a Journal Club every month as part of our Lifespan Heroes program, but, unfortunately, January saw us encounter a problem at Cooper Union University, from where the stream is broadcast and presente. This meant that we had to move the scheduled broadcast from January 30th to the 6th of February at 13:00 EST; yes, that’s right, folks, the January Journal Club is in February. On the plus side, it also means there will be two journal clubs in February, as the regular one will also happen on February 27th as normal live on our Facebook page.

The Abolition of Aging – A Book Review

As you might recall, in my review of Ending Aging, I said that the book could have benefited from a more in-depth discussion of the benefits of rejuvenation as well as the concerns and objections often raised against it. Anyone else sharing the same feeling will find what they’re looking for in The Abolition of Aging, by Chair of London Futurists David Wood.

Written in an elegant, clear style, The Abolition of Aging brilliantly accomplishes the difficult task of guiding the reader through all the turns and twists of the topic, explaining in great detail the benefits that would derive from a successful implementation of the “rejuveneering project”—as Wood calls it—presenting all the typical objections and related counterarguments, and—in the words of 3G Doctor Director David Doherty—providing innumerable “stunning references and observations”.

Just like there’s no time to waste if we want to defeat aging in time for currently living people to benefit, Wood wastes no time with lengthy preambles; the very first line of the foreword comes directly to the point, bluntly stating what readers unfamiliar with the topic may find shocking: the possibility of eliminating biological aging is now within striking distance.

Possibly preventing the reader’s reaction, the author immediately gives a preliminary discussion of the traditional responses to his claim: “it’s not possible” and “it’s not desirable”, which Wood ascribes—correctly, in my opinion—in no small part to a great desire to avoid an unpleasant discussion that would force us to reconsider many assumptions on the inevitable finitude of human existence, with which most of us have already made our peace.

To succeed in his task of getting us to snap out of a multi-millenary Stockholm syndrome that pushes humanity to praise the tyranny of old age, Wood resorts to every weapon in his arsenal, making a very convincing case that rejuvenation is very much desirable as well as possible.

Skeptics who assume that the technology necessary to rejuvenate people is centuries away will be surprised to learn about how advanced the field actually is and how much faster it is likely to grow than conventional wisdom would have it. The word of senior scientists who claim that the reversal of aging is nothing but a pipe dream, as Wood warns us, should be taken with a grain of salt: The Abolition of Aging provides plenty of examples of luminaries and eminent experts of the past summarily dismissing scientific theories and technologies that today are well-established and taken for granted by everyone. (Among many such examples, one I really cannot abstain from mentioning is the hilariously wrong 1903 prediction by the New York Times that human flight, if at all possible, would take one to ten million years to come true. Less than 70 years later, not only was human flight commonplace, but human beings had landed on the Moon.)

Nonetheless, Wood’s optimism should not be mistaken for complacency. He makes no mystery that the success of the rejuveneering project is a mere possibility, however likely, and not at all a certainty. Many are the unknowns—scientific, political, societal, financial, and more—that could well thwart our efforts in this direction if we’re not careful. Wood offers advice on how to deal with these issues standing in the way of an aging-free world as well as those that might lurk beyond. After all, the functioning of society as we know it hinges on the existence of aging; our lives, our policies, and our customs are built around it.

Eliminating aging would require a serious rethinking of much of society’s inner workings, and this operation is not free of risks, as Wood rightfully concedes. Great changes for the better often come with potential downsides, but we should not let this deter us; rather, we should appreciate how the fruits to be reaped are well worth the potential risks involved and act now to prevent or mitigate any unwanted consequences. A world without aging would need to be managed in a different way, but that is not a problem.

A particular obstacle on the way to a world without aging is represented by adverse psychology, to which Wood dedicates an entire chapter. Ever since we had the ability to reflect upon ourselves and the human condition, as the author explains, we’ve had to face our own mortality and fear of death. Fear of death is a very useful adaptation to increase the chance that an individual will live long enough to reproduce, but in the case of a highly self-aware species like us, it’s a double-edged sword. Our deep desire to express ourselves, to learn, create, grow, to live, inevitably clashes against the knowledge of our apparently inescapable demise.

If left unresolved, this inner conflict could strike terror so paralyzing that living our lives would be impossible. With no hope of defeating an apparently all-powerful enemy such as death, the young human race had to devise other ways out of this conundrum—psychological expedients to sugar the pill or even make it appear better than the alternative; for some, having children, creating art, changing the world through their work and so on may all offer the comforting thought of their legacy, and thus part of themselves, carrying on at least to some extent; believers have faith that their immortal souls will continue existing even after their bodies will have perished; others assume a world without death would, for one reason or another, be so unbearable that oblivion would be preferable.

These mental devices have existed for so long that they’ve shaped our society and our morals; accepting death has become a sign of wisdom while trying to avoid or delay it when “the right time” has come is seen as a sign of immaturity and selfishness. These views are so entrenched in most people that any attempt to question their validity is likely to trigger aggressive defensive reactions or, sometimes, contempt and ridicule. For these reasons, life extension is not an easy idea to sell. In his detailed discussion, though, Wood provides valuable advice to ease the advocates’ task, listing the dos and don’ts of how to present the subject.

Rejuvenation is not all the book deals with. Wood’s futurist soul fully reveals itself in his vision of the futures of humanity, faith, and death, which are discussed in the chapter “Towards Humanity+” as well as in the possibilities outlined in chapter 12, “Radical alternatives”, such as cryonics, head transplants, and mind uploading. While these ideas are often plagued by abundant hype and unjustified premature enthusiasm, I find that Wood simply presented relevant facts as they are, with an appropriate dose of healthy skepticism where needed but without any undue disbelief. Cryonics in particular, which is usually unjustly regarded as a scam to part rich fools from their money, is presented as a valid backup plan for those who don’t expect to live long enough to see the dawn of rejuvenation; just like cryonics companies themselves, Wood makes no mystery that it is uncertain if bringing back to life cryopreserved patients will ever be possible, despite encouraging successes with transplantation of cryopreserved animal organs. Then again, I would add that if the chances of coming back to life from cryopreservation are uncertain, there’s no chance whatsoever of coming back after being buried or cremated.

Summing up, I believe that The Abolition of Aging is a must-read for experienced advocates and newcomers alike. People who haven’t made up their minds about supporting rejuvenation will be fully equipped to make an informed decision after reading this book, or, at the very least, will be able to research the topic further; advocates will have plenty of references and useful information for their advocacy efforts. Together with Ending Aging, this book answers pretty much all the whats, whens, hows, and whys to the best of our current understanding.

 

Google’s Calico Announces Discovery Of A “Non-Aging Mammal.”

Completely bald and with wrinkly skin, the naked mole rat is one of the ugliest creatures around but lives an exceptionally long life for a small mammal. It rarely develops the chronic diseases of aging, such as cancer, and lives 10 times longer than regular rats.

The First Non-Aging Mammal

In the first significant announcement from Calico Labs since it was formed in 2013, researchers Rochelle Buffenstein, Megan Smith, and J. Graham Ruby have announced that the naked mole rat is a “non-aging mammal.”

The researchers followed the naked mole rats – housed at the Buck Institute – over a three-decade-long study period. They found that these creatures show hardly any signs of aging, such as problems with their metabolism, heart, or bones. Females do not go through menopause and continue to reproduce into their 30s, which is an amazing feat for an animal that lives at least 30 years of age in captivity. Even the cells in their bodies have a remarkable resistance to oxidative damage caused by free radicals. Small rodents the size of the naked mole rat live for no more than six years.

Senior Principal Investigator Rochelle (Shelley) Buffenstein, Ph.D. spent the early part of her career at the Medical School of the University of Witwatersrand, South Africa, where she studied the naked mole rat for ten years. Principal Investigator J. Graham Ruby, Ph.D. received his doctorate in biology from MIT and performs biometric, biostatistical, bioinformatic, and quantitative genetic analyses of diverse data to decipher the aging process in humans and model organisms. The researchers published their results on Jan 24th in the open access journal eLife[1].

How the Non-aging Mammal Was Discovered

To judge the rate of aging, the Calico team used a mathematical model called the Gompertz-Makeham law of mortality. This statistically validated law states that the risk of death for every mammal increases exponentially with increasing age. The Calico researchers used this model to analyze an existing data set of more than 3000 naked mole rats over a 30-year timespan and found that the small mammals did not conform to the Gompertz-Makeham law. Unlike every other mammal, the mole rats do not face an increased hazard of death with each birthday; as the Calico authors said, “This absence of hazard increase with age, in defiance of Gompertz’s law, uniquely identifies the naked mole-rat as a non-aging mammal.”

Estimated probability of a US person dying at each age (2003.) Credit: Uscitizenjason CC BY SA 3.0

This is astonishing given that all other mammals, including humans, face an increased rate of death with each passing birthday. Consider this hazard chart for US citizens in 2003, in which the mortality rates increase exponentially with age after the age of 30.  In contrast, the equivalent chart for the naked mole rat is almost flat.

Caleb E. Finch and Hiram Beltrán-Sánchez, a pair of scientists from the University of Southern California (USC) in Los Angeles, analyzed and commented on the study. Caleb E. Finch, Ph.D. is a molecular biologist in the Leonard Davis School of Gerontology and Dornsife College. Hiram Beltrán-Sánchez is from the Department of Community Health Sciences and the California Center for Population Research.

Commenting on the remarkable results of the study in a companion piece[2], Finch and Beltrán-Sánchez said that the naked mole rat defied the Gompertz-Makeham law, remarking, “their risk of death does not increase as they get older” and “this is unprecedented for mammals.”

Finch and Beltrán-Sánchez said that previous studies of the non-aging mammal suggest that aging creeps in, nevertheless. Naked mole rats can accumulate oxidative damage in their cells and experience muscle wasting. There is also some evidence for small amounts of cancer. But, after reviewing the evidence, the USC authors said, “This would suggest that unlike any other mammal, the naked mole rats have an extremely low rate of aging.”

Finch and Beltrán-Sánchez said that the minimal age-related problems of the mole rat combined with its long lifespan allow it to achieve ‘negligible senescence,’ a phenomenon in which an animal reaches an advanced age without increased mortality or disability.

Other scientists believe that the longevity of naked mole rats is due to the limited oxygen of their subterranean habitat. Because of this environment, their metabolic rates are abnormally slow, and an abundance of repair mechanisms keeps their cells astonishingly youthful.

About Longevityfacts

We have teamed up with our friends at Longevityfacts and will be publishing some of their articles as part of an agreed syndication deal. This article originally appeared here at Longevityfacts.

Literature

[1] J Graham Ruby, Megan Smith, Rochelle Buffenstein, Calico Life Sciences LLC. “Naked mole-rat mortality rates defy Gompertzian laws by not increasing with age.” eLife 2018;7:e31157 DOI: 10.7554/eLife.31157, Jan 24, 2018.

[2] Hiram Beltrán-Sánchez, Caleb Finch. “Life Expectancy: Age is just a number.” eLife 2018;7:e34427 DOI: 10.7554/eLife.34427 Jan 24, 2018.

Taking Care of Your Fibroblasts Might Help You Look Younger

As we age, our bodily functions begin to deteriorate. To some extent, our bodies can cope with these unwelcome changes, but after age 35, some of them become visible. For us living in a world where youth and physical attractiveness are considered an advantage, this gradual loss of young looks can be painful – or maybe even scary, if we don’t know a way to slow down or reverse it.

It is not that physical attractiveness is a value per se for me, but I often hear people say that someone promoting longevity technologies should set a good example; wrinkles, dull skin and hair, and a bloated figure discredit not only the activist but the movement as a whole.

So, I keep an eye on what is going on in the field of aesthetic medicine – especially when it comes close to and crosses with rejuvenation biotechnologies. Last week, I went to one of the flagship research organizations in Moscow – the Human Stem Cells Institute – to interview Dr. Vadim Zorin, the head of the SPRS-therapy project and the developer of a unique approach to skin rejuvenation.

Vadim, thank you very much for finding time to tell our readers about your work. Our community is interested in various approaches to slowing down the aging process. If we recall the Hallmarks of Aging published in 2013, aging of the skin (and other tissues, I suppose), is due to three mechanisms of aging: depletion of the stem cell pool, dysregulation of proteostasis (that is, the cell produces fewer proteins necessary for its normal function, or these proteins are deformed), and cellular aging. Tell us, please, how does SPRS therapy counteract these aging mechanisms?

SPRS-therapy® stands for Service for Personal Regeneration of Skin. It is a combination of personalized medical and diagnostic procedures for skin regeneration when it already carries some signs of aging and other structural changes. SPRS-therapy® is based on the technology of extracting, assessing, cultivating and using autologous (the patient’s own) fibroblasts. We have patented this technology in Russia, the European Union and the United States.

Fibroblasts are the main cellular component of the skin’s connective tissue, maintaining its homeostasis and morphofunctional organization. They perform a number of diverse and complex functions in the skin; they control the composition and structure of the components of the extracellular matrix of the dermis (collagen, elastin, proteoglycans and structural glycoproteins), and their function includes both the production of these substances and their catabolism.

Thus, fibroblasts are a key link in skin biology; they support the homeostasis of the extracellular matrix of the dermis, providing its remodeling and renewal, and they play a significant role in maintaining the physiological state of the other layers of the skin.

As the population of skin fibroblasts ages, the number of cells decreases in the skin of old people. The total number of fibroblasts is reduced by an average of 35%, and their biosynthetic activity decreases. According to G. Fisher et al., 2002, the production of collagen in the skin of old people is, on average, 75% below that of young people. The balance between the processes of synthesis and degradation of the extracellular matrix of the dermis is disturbed. The natural consequence of these processes is a decrease in the thickness and elasticity of the skin and the formation of wrinkles. Hence, the process of skin aging is ultimately caused by a decrease in the fibroblast population and a decrease in their proliferative/synthetic activity, which is naturally manifested by a decrease in the quantitative and qualitative composition of the extracellular matrix of the dermis.

So, the loss of functional fibroblasts seems to be the key enemy of those of us chasing indefinite youth, at least on the outside. How exactly does SPRS-therapy fight against these unwelcome, age-related changes?

The use of cultured autologous dermal fibroblasts (autoDF) allows us to replenish the decreased fibroblast population by introducing specialized, functionally active cells into the skin of the patient.

As early as 1994, American scientists showed that the introduction of autoDF into the skin promotes effective wrinkle correction, and a number of clinical studies have been carried out by both American and Russian scientists to confirm the effectiveness and safety of autoDF in cosmetic medicine.

Building upon this work, we developed our own method to fence, transport, isolate, cultivate, cryopreserve, store and apply autologous fibroblasts for skin rejuvenation. We took it into clinical trials and proved its positive effect. In 2010, the Human Stem Cells Institute (HSCI) in Russia received permission from the Russian Federal Service for Surveillance in the Health Care Sector to use SPRS-therapy to treat age-related and cicatricial changes in the skin. In 2011, the FDA in the United States issued a permit to another company, Fibrocell Science, to use autoDF to correct wrinkles in the area of nasolabial folds (it is called LAVIVTM, or azficel-T).

Through instrumental and morphological studies, we observed an increase in the thickness and elasticity of the skin and a decrease in the number and depth of wrinkles. This indicates that after the transplantation, cultured autoDF cells are fully integrated into the dermis, and their biosynthetic activity persists for at least 12 months. As a result, the microstructure of the dermis is remodeled, increasing its collagen fibers and thus increasing skin hydration, density, and thickness. This particular clinical effect becomes more pronounced throughout the year after the intervention, and it lasts for at least two years. Our results are consistent with the results of research conducted by the American company Fibrocell Science, which also demonstrated a significant decrease in the number of wrinkles and increased skin thickness after the use of autoDF.

Sounds pretty amazing! Of course, someone who is serious about restoring a youthful appearance won’t use just one therapy but rather a combination. This includes plastic surgery and other injection methods, such as the recently popular PRP or fillers. However, your therapy has been clinically tested, so its effect was monitored. What did your patients say, and how many years younger did they look after the course of treatment? How exactly do you measure the results?

It is difficult to say how much younger it is after SPRS-therapy, since such studies have not yet been conducted by anyone, but we can definitively measure changes in the metrics that are “responsible” for the youth and beauty of skin, including its thickness, density and hydration, intensity of pigment spots, and number and depth of wrinkles. Our clinical analysis of the skin’s condition (on a 5-point scale) showed that one month after the injection, 88% of the patients rated the result as “good” and “excellent”, but after 3, 6, 12, and 24 months, it was 100% of patients.

We performed histological studies; simultaneously with the introduction of the autoDF into the skin, we injected our participants in a spot behind the auricle for subsequent biopsies at 1, 3, 6, 12 and 24 months. We conducted morphometric evaluation of the thickness of the dermis and impregnated it with silver nitrate in order to detect newly formed collagen fibers. Our immunohistochemistry studies revealed prolonged biosynthetic activity of transplanted autoDF for at least 12 months, which was expressed in the synthesis of components of the cellular matrix and an increase in the thickness of the dermis by an average of 63% over those 12 months. We also evaluated microcirculation with laser Doppler flowmetry (laser blood flow analyzer), elasticity with cutometry (Cutometer MPA 580, Courage + Khazaka Electronic GmbH), skin texture and wrinkles using the VISIA photometric system (Proctor & Gamble Co), and wrinkle depth by means of optical profilometry (PRIMOS, GFMesstechnik GmbH).

These measurements showed a significant increase in the elasticity and thickness of the skin, a decrease in the intensity of pigment spots, and a decrease in the number and depth of wrinkles.

It is wonderful that we have a way to achieve external rejuvenation. Moreover, this affects not only the condition of the skin but also the common problem of hair loss. As I understand it, this is especially important for men; what is the proportion of the male population among your patients?

About one-third of our patients are men.

Is it possible to restore the pigmentation of hair in people who have already turned gray?

To date, no, it’s not currently possible. This is a very complex process, since physiological graying is associated with the natural aging of other cells, specifically melanocytes, and early graying, as a rule, is due to their death or decreased activity due to hormonal disorders. As a result, the hair is deprived of the pigment, it acquires a porous structure, and the air between the layers gives the affected hair a silvery white hue. We cannot stop the process of graying because melanocytes begin to work even in the prenatal period of human development and gradually regress with age. Every 10 years after the age of 30, their function fades by 10-20% and hair begins to appear with no pigment in the keratin. With the withering away of all the melanocytes supplying melanin to the hair shaft, the hair becomes completely gray.

A more difficult question is whether this approach is applicable to the restoration of other tissues and organs, or does SPRS only allow you to restore the skin? If there are restrictions, then what are they related to?

SPRS-therapy is aimed at restoring only the skin because it is based on the use of skin fibroblasts. However, in the arsenal of our company, there is another authorized technology: SPRG-therapy (patented in Russia in 2010), which is based on the use of fibroblasts of the oral mucosa, which allows the restoration of soft periodontal tissue. So, we can say that this technology can be adapted to some of other cell types, but each new type requires its own set of production processes and, of course, clinical studies.

Last year, our community was enthused by news from the Salk Institute, where due to reprogramming of adult cells with Yamanaka factors, the researchers managed to partially reverse some age-related changes in mice, such as muscular dystrophy or age-related metabolic disorders. What do you think about the combination of SPRS and the short-term application of Yamanaka factors on cell culture? Can the further development of SPRS therapy go in this direction?

Yes, of course, the reprogramming of autologous skin fibroblasts will allow obtaining personalized induced pluripotent cells (iPSCs), which can be considered innovations towards autogenous therapy of a wide range of diseases, and iPSCs are also useful for drug screening. However, it should be noted that, despite the promising therapy options based on autologous iPSCs, this technology is still at an early stage of development. Further research is needed, including a detailed study of the biological and cancer-related safety of these cells, an analysis of their chromosomal stability both in early and late passages, and a complex analysis of their differentiation potential.

At the moment, SPRS therapy is quite expensive; the price for one course of treatment can be more than $5,000. For this anti-aging approach to become available to the masses, the price should be significantly reduced. HSCI has a very positive history with regards to reducing the price of an innovative product. I’m talking about gene therapy, which is developed at the institute. Your Neovasculgen is designed to stimulate vascular growth in a limb in order to replace vessels lost due to severe limb ischaemia. Over the past couple of years, you have been able to reduce the price of Neovasculgen more than two-fold, and now it costs around $1,500 – probably the most affordable gene therapy in the world. It was a hard decision for you of course, as this price can barely recoup what you invested into the research behind it, but it allowed you to have this gene therapy included in the list of essential medicines in Russia, which improves access to it. Can we expect similar breakthroughs in the case of SPRS?

It is necessary to understand that in the case of SPRS therapy, we do not work directly with patients; the final price for the patient is set by the clinics, with which we work in terms of bilateral agreements. Quite often, to our great regret, the final price is triple our production cost (i.е. what we spend to produce the cell culture for one individual patient), and in some clinics, it is quadruple or quintuple! Now, we are trying to work with new clinics to reduce their costs so that we can make this therapy affordable for more people.

In addition to helping people to become younger, you often write in your blog about your personal health strategy. What elements, in your opinion, should be the basis of such a strategy? What methods of slowing aging do you consider to be sufficiently scientifically valid, and what are you personally using?

What happens to us with increasing age? First, an increase in food intake; second, a decrease in motor activity; and third, a decrease in the body’s ability to mobilize fats. Starting at age 30, alas, the fat content in the body begins to increase, but the net body weight – due to the reduction of muscle tissue and demineralization of bone tissue – begins to decrease. It is caused by many factors, not least of which is the same decrease in motor activity due to metabolic processes deteriorating with age. This becomes a vicious cycle. Therefore, the algorithm is very simple.

1) Increased physical activity, which leads to greater energy expenditure. What kind of training is the easiest and most useful? Ordinary walking or, better yet, Nordic walking in the cardiological step (ideally 5-6 km/h with a pulse rate of 120 beats per minute). This is a training in the so-called aerobic zone, i.e. low-intensity and long-term physical activity.

I am an adherent of Nordic walking, which employs up to 85% of the muscles of the body and, in addition, supports energy metabolism, pulmonary ventilation and muscle tone, which plays an important role in preventing the development of ischaemic heart disease. However, since any physical activity should be appropriate for age and health status, it is mandatory to control the pulse (heart rate). To monitor my pulse, distance and speed in real time, I use the Runtastic PRO program installed on my mobile phone. My standard training is to walk for at least 3 times a week for a minimum of 30 to 40 minutes. Incidentally, exercise not only strengthens and increases muscle and bone tissue (and we have neither more nor less than 206 bones and more than 640 muscles), it also stimulates the activity of stem cells that are responsible for maintaining the number of cells inhabiting their tissues.

2) Deliberate diet control. Calorie restriction prolongs life in any organism from yeast to primates, including humans. In 2007, evidence of this phenomenon appeared at the cellular level when American scientists, led by Dr. Sinclair (published in the prestigious scientific journal Cell), discovered the genes SIRT3 and SIRT4. The activation of these genes leads to an increase in the same proteins as the family of sirtuins, which are important regulators of slowing the aging of cells and increasing longevity. In general terms, this is the case. There are “power plants” – mitochondria – in the cytoplasm of our cells. When the calories entering the cell are reduced, relevant signals enter the mitochondria and activate a specific NAMPT gene in them, which leads to an increase in the production of certain molecules (the so-called NAD – the main energy carriers in the cell), which, in turn, activate the SIRT3 and SIRT4 genes. The proteins expressed by these genes lead to an improvement in energy metabolism in the cell, and this, in turn, leads to a slower aging of the cell and prevents apoptosis (premature cell death).

As a result, the body slows down the aging process, the development of age-related diseases is delayed, and, accordingly, the lifespan is increased.

This mechanism is proved by the results of a 25-year study published in Nature Communications in 2014. This study was conducted by a team of scientists from the University of Wisconsin-Madison on rhesus macaques. Macaques on a low-calorie diet had normal body weight, a decrease in the rate of loss of muscle mass (which, as is known, accelerates with age), a significant reduction in the risk of developing diabetes and cardiovascular diseases, and an increased lifespan of 30 years or more, despite the fact that the average life expectancy in captivity for these animals is about 26. Incidentally, Sinclair and colleagues assert that exercise exerts the same effect on the body as a low-calorie diet!

3) And, of course, do not forget about the sauna, unless it is contraindicated for health reasons. A sauna offers relaxation, dilates blood vessels, and may reduce the risk of developing respiratory and cardiovascular diseases, senile dementia and even Alzheimer’s disease!

We often ask researchers what their forecast is regarding medical technologies for addressing aging. Do you think that science will be able to defeat aging and thereby prevent age-dependent diseases? What can we do as a community to make this happen sooner?

I think that someday in the future it will happen. It may not be exactly defeating aging but rather increasing the life expectancy and significantly improving the quality of life. However, a lot has already been done in this respect. Which directions do I find promising? Here they are:

1) Gene therapy. In the laboratory, we have already managed to prolong the life of nematode worms, fruit flies, and mice. In humans, genes responsible for prolonging life have also been identified.

2) Cell therapy. Today, a lot of clinical studies are conducted on the treatment of so-called classical age-related diseases by introducing allogenic mesenchymal stromal cells (MSCs) into the damaged parts of the brain and heart, which significantly improves the condition of patients who have suffered strokes and heart attacks. In 2017, a randomized, blind, placebo-controlled clinical trial was conducted in 30 patients with senility syndrome, who were intravenously injected with allogeneic MSCs from young healthy donors. The results of the study showed a significant improvement in physical health in these patients as well as a decrease in the content of inflammatory biomarkers that are specific to this syndrome.

With the help of cell therapy, good results have also been obtained in the restoration of bones, joints, and skin. At present, many leading laboratories in the world have made considerable progress in studying induced pluripotent cells (iPSCs). These cells are desirable because, on the one hand, they have the properties of embryonic stem cells (ESCs) that make them capable of differentiating into any type of cell in the body, and on the other hand, their use makes it possible to avoid the ethical and other problems associated with ESCs. These cells enable the creation of innovative technologies for autogenous therapy of a wide range of diseases, including, of course, age-related pathologies.

3) Growing and transplanting organs. We have already learned to grow in laboratories not only cartilaginous tissue, skin, and blood vessels but also the ureter, bladder, and other hollow organs. The researchers are also working on the creation of artificial hearts and lungs. In short, the prospects are very bright.

What can we do as a society? Increase education and put a maximum of effort into supporting the progress of science and medicine.

I cannot agree more. Thank you very much for your time, Vadim! We wish you and your wife and research partner Alla good luck in further studies!